See the DrugPatentWatch profile for keytruda
Yes, specific populations may be at a higher risk for rare Keytruda (pembrolizumab) adverse events. Keytruda is a type of immunotherapy drug called a programmed death receptor-1 (PD-1) inhibitor, which helps the immune system fight cancer [1]. While Keytruda has been approved by the FDA for various cancer indications, it can cause severe and potentially fatal adverse reactions [2].
According to the Keytruda Prescribing Information, some populations may be more susceptible to certain adverse events:
1. Immune-Mediated Adverse Reactions: These can occur during or after Keytruda treatment and affect various organs [2]. Patients with a history of autoimmune disorders or those who receive Keytruda in combination with other immunosuppressive treatments may be at a higher risk [2].
2. Infusion Reactions: These typically occur during the infusion but may also happen after [2]. Patients with a history of severe or life-threatening infusion reactions to Keytruda or its excipients should not receive the drug [2].
3. Comorbidities: Patients with a history of interstitial lung disease, human immunodeficiency virus (HIV) infection, hepatitis B or C, or those who have received organ transplants may be at a higher risk for certain adverse events [2].
4. Use in Specific Populations: Pregnant women should not use Keytruda due to potential fetal harm [2]. Safety and effectiveness in pediatric patients have not been established [2].
It is essential to monitor patients closely for signs and symptoms of adverse reactions and to manage them promptly [2]. Healthcare professionals should report all serious adverse events suspected to be associated with Keytruda to the FDA's MedWatch program [2].
Sources:
[1] DrugPatentWatch.com. (n.d.). Keytruda (pembrolizumab). Retrieved from
https://www.drugpatentwatch.com/drugs/keytruda
[2] Merck Sharp & Dohme Corp. (2021). Keytruda (pembrolizumab) Prescribing Information. Retrieved from
https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf